Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion
Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
Read the full story at Bloomberg Markets ↗
ImpactMinor 20/100
Why it mattersRule-based estimate: event keywords (+6), soft/evergreen signals; trust 9/10.
RegionsGlobal
Published1 h ago (Fri, 02 Oct 2026 06:47:06 GMT)
RetrievedFri, 02 Oct 2026 07:00:28 GMT via rss
ClassifiedFri, 02 Oct 2026 07:00:41 GMT by heuristic
AuthorAmber Tong